Skip to main
VNDA
VNDA logo

Vanda Pharmaceuticals (VNDA) Stock Forecast & Price Target

Vanda Pharmaceuticals (VNDA) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vanda Pharmaceuticals Inc. is demonstrating strong financial performance and positive growth indicators, particularly with its product Fanapt, which experienced a 27% year-over-year revenue growth in Q2 2025 and continued to accelerate to a 31% increase in Q3 2025, potentially nearing a $120 million annual run-rate. Additionally, new patient prescriptions for Ponvory reached record highs in Q2 2025, indicating robust demand, with projected gross sales expected to escalate from $9.4 million in 2027 to $172.8 million by 2034, bolstered by strategic commercial initiatives and increased prescriber awareness. The company's investments in promotional programs have resulted in significant increases in prescription metrics for both Fanapt and Ponvory, with notable growth in new prescriptions, reflecting Vanda's successful execution of its commercial strategy amidst an expansive market potential.

Bears say

Vanda Pharmaceuticals Inc reported net product sales of $7.1 million in Q2 2025, a decline of 18% year-over-year, which reflects disruption from recent acquisitions and adjustments in specialty pharmacy channels. The company's revenue outlook is further challenged by the anticipated erosion of exclusivity for its key products by the end of 2027, coupled with the expected rapid decline in Fanapt sales due to competition from new market entrants. Additionally, the commercial trajectory for other treatments, such as Ponvory, remains uncertain following a period of neglect, which has negatively impacted prescriber awareness and could result in significant revenue loss as generics emerge and pricing pressures escalate.

Vanda Pharmaceuticals (VNDA) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vanda Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vanda Pharmaceuticals (VNDA) Forecast

Analysts have given Vanda Pharmaceuticals (VNDA) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Vanda Pharmaceuticals (VNDA) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vanda Pharmaceuticals (VNDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.